 |
2 Products |  |
0 Diseases | | 2 Products |
|
4 Trials |  |
524 News |  |
| «1234567» |
- | Bylantra (devimistat) / Cornerstone Pharma
New P2 trial: CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 14, 2017
P2, N=45, Not yet recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P1/2 trial, Combination therapy: CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 12, 2017
P1/2, N=58, Not yet recruiting, Sponsor: Wake Forest University Health Sciences
- | Bylantra (devimistat) / Cornerstone Pharma
Trial primary completion date, Surgery, Metastases: CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Aug 17, 2017
P1/2, N=13, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: May 2017 --> Feb 2018
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial primary completion date, Combination therapy: 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 1, 2017
P1/2, N=0, Withdrawn, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: May 2017 --> Feb 2018 Trial primary completion date: Dec 2017 --> Jul 2016
- Bylantra (devimistat) / Cornerstone Pharma
Enrollment change, Trial termination, Combination therapy: A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients (clinicaltrials.gov) - Mar 21, 2017
P1/2, N=6, Terminated, Sponsor: Cornerstone Pharmaceuticals, Inc.
Trial primary completion date: Dec 2017 --> Jul 2016 N=60 --> 6 | Suspended --> Terminated; Suspended trial was not restarted.
- | Bylantra (devimistat) / Cornerstone Pharma
Trial primary completion date, Combination therapy: CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (clinicaltrials.gov) - Mar 14, 2017
P1, N=14, Recruiting, Sponsor: Wake Forest University Health Sciences
N=60 --> 6 | Suspended --> Terminated; Suspended trial was not restarted. Trial primary completion date: Jan 2017 --> Jan 2018
- | Bylantra (devimistat) / Cornerstone Pharma
Trial primary completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 14, 2017
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Jan 2016 --> Jan 2018
- | Bylantra (devimistat) / Cornerstone Pharma
Trial suspension, Trial primary completion date, Combination therapy: A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients (clinicaltrials.gov) - Jan 9, 2017
P1/2, N=60, Suspended, Sponsor: Cornerstone Pharmaceuticals, Inc.
Trial primary completion date: Jan 2016 --> Jan 2018 Active, not recruiting --> Suspended | Trial primary completion date: Dec 2014 --> Dec 2017
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Phase classification, Enrollment change, Trial withdrawal: Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 29, 2016
P2a, N=0, Withdrawn, Sponsor: Cornerstone Pharmaceuticals, Inc.
Active, not recruiting --> Suspended | Trial primary completion date: Dec 2014 --> Dec 2017 Phase classification: P2 --> P2a | N=30 --> 0 | Not yet recruiting --> Withdrawn
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial completion, Trial primary completion date, Metastases: A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 29, 2016
P1/2, N=39, Completed, Sponsor: Cornerstone Pharmaceuticals, Inc.
Phase classification: P2 --> P2a | N=30 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2016
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment change, Trial termination, Trial primary completion date: Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients (clinicaltrials.gov) - Dec 29, 2016
P2, N=7, Terminated, Sponsor: Cornerstone Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2016 N=100 --> 7 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Dec 2016
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial completion, Enrollment change, Trial primary completion date: CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov) - Dec 28, 2016
P1, N=15, Completed, Sponsor: Wake Forest University Health Sciences
N=100 --> 7 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Dec 2016 Active, not recruiting --> Completed | N=20 --> 15 | Trial primary completion date: Dec 2016 --> Dec 2015
- Bylantra (devimistat) / Cornerstone Pharma
Trial completion, Trial primary completion date, Metastases: CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 28, 2016
P1, N=10, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed | N=20 --> 15 | Trial primary completion date: Dec 2016 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Oct 2015
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial completion: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 28, 2016
P1, N=67, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Oct 2015 Active, not recruiting --> Completed
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial primary completion date: CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy (clinicaltrials.gov) - Nov 15, 2016
P2, N=20, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Trial primary completion date: Aug 2016 --> Aug 2018
- Bylantra (devimistat) / Cornerstone Pharma, Rituxan (rituximab) / Roche
Trial termination, Trial primary completion date, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 2, 2016
P1, N=1, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Aug 2016 --> Aug 2018 Active, not recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Feb 2015; Slow Accruals
- Bylantra (devimistat) / Cornerstone Pharma
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 15, 2016
P1, N=10, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Feb 2015; Slow Accruals Recruiting --> Active, not recruiting | N=13 --> 10 | Trial primary completion date: Apr 2017 --> Aug 2016
- Bylantra (devimistat) / Cornerstone Pharma, Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Aug 15, 2016
P1, N=1, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting | N=13 --> 10 | Trial primary completion date: Apr 2017 --> Aug 2016 Recruiting --> Active, not recruiting | N=14 --> 1 | Trial primary completion date: Dec 2016 --> Aug 2016
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment change, Trial withdrawal, Combination therapy: 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 28, 2016
P1/2, N=0, Withdrawn, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting | N=14 --> 1 | Trial primary completion date: Dec 2016 --> Aug 2016 N=64 --> 0 | Not yet recruiting --> Withdrawn
- Bylantra (devimistat) / Cornerstone Pharma
Trial primary completion date, Combination therapy: CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (clinicaltrials.gov) - Jul 28, 2016
P1, N=14, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=64 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Jan 2016 --> Jan 2017
- Bylantra (devimistat) / Cornerstone Pharma
Trial primary completion date, Metastases: CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jul 28, 2016
P1, N=13, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Jan 2016 --> Jan 2017 Trial primary completion date: Apr 2016 --> Apr 2017
- Bylantra (devimistat) / Cornerstone Pharma
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jan 25, 2016
P1, N=21, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Apr 2016 --> Apr 2017 Recruiting --> Active, not recruiting | N=15 --> 21 | Trial primary completion date: Apr 2016 --> Jan 2016
- Bylantra (devimistat) / Cornerstone Pharma
Trial primary completion date, Metastases: CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 29, 2015
P1, N=13, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting | N=15 --> 21 | Trial primary completion date: Apr 2016 --> Jan 2016 Trial primary completion date: Nov 2015 --> Apr 2016
- Bylantra (devimistat) / Cornerstone Pharma
Trial primary completion date, Surgery, Metastases: CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 29, 2015
P1/2, N=13, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Nov 2015 --> Apr 2016 Trial primary completion date: May 2016 --> May 2017
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial initiation date, Trial primary completion date, Combination therapy: 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 23, 2015
P1/2, N=64, Not yet recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: May 2016 --> May 2017 Initiation date: Jul 2015 --> Dec 2015 | Trial primary completion date: Jul 2017 --> Dec 2017
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment open: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma (clinicaltrials.gov) - Sep 30, 2015
P2, N=50, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Initiation date: Jul 2015 --> Dec 2015 | Trial primary completion date: Jul 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial primary completion date: CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy (clinicaltrials.gov) - Sep 24, 2015
P2, N=20, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Aug 2016
- Bylantra (devimistat) / Cornerstone Pharma
Trial primary completion date, Metastases: CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 24, 2015
P1, N=13, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Jul 2015 --> Nov 2015
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment closed: CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov) - Sep 21, 2015
P1, N=20, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Jul 2015 --> Nov 2015 Recruiting --> Active, not recruiting
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial primary completion date, Metastases: A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=40, Active, not recruiting, Sponsor: Cornerstone Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P2 trial: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma (clinicaltrials.gov) - Jun 29, 2015
P2, N=50, Not yet recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Phase classification: CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov) - Jun 24, 2015
P1, N=20, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Dec 2014 --> Dec 2015 Phase classification: P=N/A --> P1
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Phase classification: CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy (clinicaltrials.gov) - Jun 24, 2015
P2, N=20, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Phase classification: P=N/A --> P1 Phase classification: P=N/A --> P2
- Bylantra (devimistat) / Cornerstone Pharma
Phase classification, Trial primary completion date, Surgery, Metastases: CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 24, 2015
P1/2, N=13, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Phase classification: P=N/A --> P2 Phase classification: P=N/A --> P1/2 | Trial primary completion date: May 2015 --> May 2016
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment closed: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 24, 2015
P1, N=61, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Phase classification: P=N/A --> P1/2 | Trial primary completion date: May 2015 --> May 2016 Recruiting --> Active, not recruiting
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P1/2 trial, Combination therapy: 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 16, 2015
P1/2, N=64, Not yet recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment open: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 20, 2015
P1, N=61, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment closed, Trial primary completion date: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 27, 2015
P1, N=61, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial initiation date, Trial primary completion date: Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 5, 2015
P2, N=30, Not yet recruiting, Sponsor: Cornerstone Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016 Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Dec 2016 --> Dec 2018
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment open, Surgery, Metastases: CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 19, 2014
P1, N=40, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Dec 2016 --> Dec 2018 Not yet recruiting --> Recruiting
- Bylantra (devimistat) / Cornerstone Pharma, Rituxan (rituximab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 6, 2014
P1, N=14, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Dec 2014 | Trial primary completion date: Aug 2016 --> Dec 2016
- Bylantra (devimistat) / Cornerstone Pharma
Trial primary completion date, Combination therapy: CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (clinicaltrials.gov) - Nov 3, 2014
P1, N=14, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Dec 2014 | Trial primary completion date: Aug 2016 --> Dec 2016 Trial primary completion date: Sep 2017 --> Jan 2016
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment change: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 30, 2014
P1, N=61, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Sep 2017 --> Jan 2016 N=20 --> 61
- Bylantra (devimistat) / Cornerstone Pharma
Enrollment open, Combination therapy: CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (clinicaltrials.gov) - Sep 19, 2014
P1, N=14, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=20 --> 61 Not yet recruiting --> Recruiting
- Bylantra (devimistat) / Cornerstone Pharma
Trial primary completion date, Surgery, Metastases: CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=13, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2014 --> May 2015
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P1 trial, Surgery, Metastases: CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 5, 2014
P1, N=40, Not yet recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial completion, Enrollment change, Metastases: Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies (clinicaltrials.gov) - Sep 4, 2014
P1, N=26, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Apr 2014 --> May 2015 Active, not recruiting --> Completed | N=20 --> 26
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial primary completion date: CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=20, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed | N=20 --> 26 Trial primary completion date: Aug 2014 --> Aug 2015
- Bylantra (devimistat) / Cornerstone Pharma
New P1 trial, Combination therapy: CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (clinicaltrials.gov) - Jun 22, 2014
P1, N=14, Not yet recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- Bylantra (devimistat) / Cornerstone Pharma, Rituxan (rituximab) / Roche
New P1 trial, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 22, 2014
P1, N=14, Not yet recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University